LRRC1 and non-small cell lung carcinoma: For example, sEVs miR-193a derived from bone marrow mesenchymal stem cells inhibited the progression of cisplatin-resistant NSCLC by targeting leucine-rich repeat containing protein 1 (Wu et al., 2020a).